Examkin

Question

Difficulty: Very hardInfectious Diseases

Evaluate the following clinical presentations of immunocompromised patients with opportunistic infections. Match each clinical scenario with the most appropriate initial targeted pharmacotherapy.

  • A 45-year-old renal transplant recipient with known severe G6PD deficiency presents with hypoxia (PaO2 65 mmHg on room air). Bronchoalveolar lavage fluid silver stain reveals cup-shaped cysts.Intravenous pentamidine
  • A 32-year-old patient with untreated HIV (CD4 45 cells/mm³) presents with subacute headache and basilar meningeal enhancement on MRI. CSF shows marked lymphocytic pleocytosis and very low glucose; CSF cryptococcal antigen is negative.Isoniazid, rifampin, pyrazinamide, ethambutol, and adjunctive dexamethasone
  • A 58-year-old profoundly neutropenic patient post-induction chemotherapy presents with persistent fever and a pulmonary nodule with a surrounding halo of ground-glass opacity. Serum galactomannan is markedly elevated.Intravenous voriconazole
  • A 28-year-old cave explorer presents with fever, hepatosplenomegaly, palatal mucosal ulcers, and pancytopenia. Bone marrow biopsy reveals small intracellular yeast forms packed within macrophages.Liposomal amphotericin B
  • A 50-year-old heart transplant recipient presents with new-onset seizures and a single ring-enhancing brain lesion. Stereotactic brain biopsy reveals delicate, branching, Gram-positive, weakly acid-fast bacilli.High-dose trimethoprim-sulfamethoxazole

Answer

The correct matches require correlating the clinical and pathologic description with the pathogen: Pneumocystis jirovecii in a G6PD-deficient patient requires intravenous pentamidine; Tuberculous meningitis requires RIPE plus dexamethasone; Invasive aspergillosis requires intravenous voriconazole; Severe disseminated histoplasmosis requires liposomal amphotericin B; and Central nervous system nocardiosis requires high-dose trimethoprim-sulfamethoxazole.
Each pair correctly matches a specific opportunistic pathogen, identified by definitive clinical and diagnostic findings, with its first-line evidence-based pharmacotherapy, specifically taking into account critical patient-level constraints such as immune status, infection severity, and genetic enzyme deficiencies.

Step-by-Step Solution

1
Identify the causal opportunistic pathogen for each clinical scenario based on pathognomonic historical, radiographic, and pathologic clues.
Scenario 1: Pneumocystis jirovecii. Scenario 2: Mycobacterium tuberculosis. Scenario 3: Aspergillus fumigatus. Scenario 4: Histoplasma capsulatum. Scenario 5: Nocardia species.
Accurate pathogen identification is the prerequisite for selecting targeted antimicrobial therapy.
2
Determine the standard first-line targeted therapy for each identified pathogen, modifying the choice based on strict patient-specific contraindications or required adjunctive therapies.
PCP standard therapy (TMP-SMX) is contraindicated by G6PD deficiency, necessitating IV pentamidine. TB meningitis strictly requires adjunctive corticosteroids alongside RIPE therapy to prevent fatal inflammation.
Rote memorization of first-line agents fails in complex clinical scenarios where host factors (e.g., enzyme deficiencies, critical CNS inflammation) dictate life-saving modifications to the standard regimen.

Key Concept

Diagnosis and targeted pharmacotherapy of complex opportunistic infections in immunocompromised hosts, requiring strict adherence to patient-specific contraindications.
Estimated Time:3m 0s
Rate this question

Topics

Infectious Diseases

More questions from this topic